Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptiMATe trial of optimized MATRix chemotherapy for newly diagnosed primary central nervous system lymphoma
ISRCTN14742241Phase 3Active, not recruiting
- Sponsor
- Klinikum Stuttgart
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rituximab, methotrexate, cytarabine, thiotepa and carmustine in primary central nervous system lymphoma (PCNSL) and Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by Klinikum Stuttgart. Primary endpoint: Event-free survival. Started Dec 2022; status: active, not recruiting.
02
Drugs
rituximabmethotrexatecytarabinethiotepacarmustine
03
Conditions
primary central nervous system lymphoma (PCNSL)Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ISRCTN14742241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14742241.